• FDA cleared Pasithea Therapeutics' investigational new drug application for a Phase 2 trial of PAS-004 in NF1-associated cutaneous neurofibromas.
• The randomized, double-blind, placebo-controlled trial will evaluate three once-daily doses in approximately 200 adults.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130200PRIMZONEFULLFEED9877062) on November 13, 2026, and is solely responsible for the information contained therein.